Industries > Pharma > Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028

Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028

ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents (ESAs), diuretic, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

PUBLISHED: 05 December 2017
PAGES: 171
PRODUCT CODE: PHA0265
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0265 Categories: ,

The Global Chronic Kidney Disease (CKD) Drugs market reached $12.2bn in 2016 and is expected to grow at a CAGR of 3.9% in the first half of the forecast period. The market is dominated by calcium channel blockers and ACE inhibitors.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 171-page report you will receive 85 tables and 93 figures – all unavailable elsewhere.

The 171-page report provides clear detailed insight into the Global Chronic Kidney Disease (CKD) Drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Chronic Kidney Disease (CKD) Drugs market forecasts from 2018-2028

• This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by drug class:
– ACE inhibitors
– Angiotensin-II receptor blockers
– Calcium channel blockers
– Beta blockers: BREVIBLOC, Bystolic
– Erythropoiesis-stimulating agents (ESAs)
– Diuretics
– Others

This report provides a SWOT Analysis for each drug class.

• This report provides revenue forecast for these leading drugs:
– Aceon
– Lisinopril
– Losartan
– AVAPRO
– Twynsta
– BREVIBLOC
– Bystolic
– Mircera
– Epoetin Alfa BS
– Natrilix SR
– Spironolactone
– Urief
– AURYXIA

• This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by distribution channel:
– Retail Pharmacies
– Hospital Pharmacies
– Online Pharmacies
– Others

• This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by regional and national market:
– North America: US and Canada
– Europe: Germany, the UK, France, Spain, Italy, Rest of Europe
– Asia-Pacific: Japan, China, India, Rest of Asia-Pacific
– Latin America: Brazil, Mexico, Rest of Latin America
– Middle East & Africa: Saudi Arabia, South of Africa, Rest of MEA

Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028

Each regional market is further broken down by drug class and distribution channel.

• This report provides company overview, financial information, product portfolio and recent developments for the leading companies in the Global Chronic Kidney Disease (CKD) Drugs market:
– Pfizer, Inc.
– Amgen
– Roche
– GlaxoSmithKline (GSK)
– Allergan
– AbbVie
– Kissei Pharmaceutical Co., Ltd.

Buy our report today Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028: ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents (ESAs), diuretic, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028

    Download sample pages

    Complete the form below to download your free sample pages for Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028

      Latest Pharma news

      Visiongain Publishes Antibiotics Market Report 2023-2033

      The antibiotics market was valued at US$44,567.3 million in 2022 and is projected to grow at a CAGR of 4.15% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Clinical Trial Supplies Market Report 2023-2033

      The global Clinical Trial Supplies market was valued at US$ 2,617.7 million in 2022 and is projected to grow at a CAGR of 9.32% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Meningococcal Vaccines Market Report 2023-2033

      The global Meningococcal Vaccines market was valued at US$3,268.6 million in 2022 and is projected to grow at a CAGR of 6.32% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Human Microbiome Market Report 2023-2033

      The global Human Microbiome market was valued at US$186.8 million in 2022 and is projected to grow at a CAGR of 25% during the forecast period 2023-2033.

      30 January 2023

      READ